RxDoctor Payments Data

Janelle Bennett, MD

Hematology & Oncology · Fremont, CANPI 1659682094

Payments from drug & device makers

$3,485in general payments, 2019–2025

Across 183 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$377
  • AstraZeneca$296
  • Lilly USA, LLC$252
  • Pfizer$198
  • Bristol Myers Squibb$181
  • Novartis$171
  • plus $2K from 37 others

What the payments were for

  • Travel & lodging$37711%
  • Food & beverage$2,90683%
  • Education$2026%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,485 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$167,190
Medicare patients
321
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide37$561,401
PomalystPomalidomide15$337,760
JakafiRuxolitinib Phosphate13$229,583
ImbruvicaIbrutinib11$180,210
EliquisApixaban23$20,826
XareltoRivaroxaban16$8,864
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen127$4,228
Letrozole105$2,406
Anastrozole81$1,891
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen70$1,875
Morphine Sulfate ErMorphine Sulfate26$1,698
Ondansetron Hcl66$1,338
Exemestane16$811
Oxycodone Hcl47$809
Tamoxifen Citrate21$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$181$561,40137 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$162$337,76015 claims
Incyte CorporationJakafi$12$229,58313 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$96$180,21011 claims
PfizerEliquis$198$20,82623 claims
Johnson & JohnsonXarelto$16$8,86416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →